WHAT IS CLAIMED IS:

1. A suspension formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL suspended in a non-aqueous suspension vehicle with a viscocity of less than 20 centipoise at about 25 °C, wherein the non-aqueous suspension vehicle comprises propylene glycol dicaprylate/dicaprate.

2. The formulation of claim 1 wherein the viscosity of the suspension vehicle is less than 10 centipoise at about 25 °C.

~~3. The formulation of claim 2 wherein the viscosity of the suspension vehicle is less than 5 centipoise at about 25 °C.~~

~~4~~3. The formulation of any one of the preceding claims wherein the injection glide force of the formulation is 20 newton or less, and wherein the injection glide force is determined as a function of antibody concentration by injecting 1-mL of the suspension using a 1-mL long syringe through a 27-gauge thin walled staked needle in 10 seconds.

~~5~~4. The formulation of any one of the preceding claims wherein the average particle size in the formulation is from 2 microns to 30 microns.

~~6~~5. The formulation of any one of the preceding claims further comprising a sachharide.

~~7~~6. The formulation of claim ~~6~~ 5 wherein the saccharide is trehalose or sucrose.

~~8~~7. The formulation of claim ~~6~~ 5 or ~~7~~ 6 wherein the molar ratio of saccharide: monoclonal antibody is from 50 to 400:1.

~~9~~8. The formulation of claim ~~8~~ 7 wherein the molar ratio of saccharide: monoclonal antibody is from 100 to 250: 1.

~~10~~9. The formulation of any one of the preceding claims further comprising a nonionic surfactant.

~~11~~10. The formulation of claim ~~10~~ 9 wherein the surfactant is polysorbate 20 or polysorbate 80.

~~12~~11. The formulation of any one of the preceding claims which is suitable for subcutaneous administration.

~~13~~12. The formulation of any one of the preceding claims wherein the monoclonal antibody is a full length monoclonal antibody.

~~14~~13. The formulation of claim ~~13~~ 12 wherein the monoclonal antibody is a human IgG1.

~~15~~14. The formulation of any one of the preceding claims wherein the monoclonal antibody is a chimeric, humanized, or human antibody.

~~16~~15. The formulation of any one of the preceding claims wherein the monoclonal antibody binds an antigen selected from the group consisting of: CD20, HER2, VEGF, IL6R, beta7, Abeta, HER3, EGFR, and M1'.

~~17~~16. The formulation of claim ~~16~~ 15 wherein the antibody is rituximab, trastuzumab, or bevacizumab.

~~18~~17. A subcutaneous administration device with the formulation of any one of the preceding claims therein.

~~19~~18. The device of claim ~~18~~17, which comprises a pre-filled syringe.

~~20~~19. A method of making a suspension formulation comprising suspending a spray dried monoclonal antibody in a non-aqueous suspension vehicle with a viscosity less than 20 centipoise at 25 °C, wherein the monoclonal antibody concentration in the suspension formulation is about 200 mg/mL and wherein the non-aqueous suspension vehicle comprises propylene glycol dicaprylate/dicaprate.

~~21~~20. A method of making an article of manufacture comprising filling a subcutaneous administration device with the formulation of any one of claims 1 to ~~17~~16.

~~22~~21. Use of the formulation of any one of claims 1 to ~~17~~ 16 in the preparation of a medicament for treating cancer, autoimmune disease, age-related macular degeneration or macular edema.

~~23~~22. The use of claim ~~22~~ 21 wherein the formulation is for administration to the patient subcutaneously.

~~24~~23. The use of claim ~~22~~ 21 or ~~23~~ 22 wherein the formulation is for administration using a pre-filled syringe containing the formulation therein.